Sign in
Taking peoplePhase 2

FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients previously treated for Waldenström macroglobulinemia"

Key facts

Who runs it
French Innovative Leukemia Organization
Where
France40 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
102 people, planned
Started
20 Jan 2026
Expected to end
31 Dec 2030
Type of study
Interventional
Record updated
30 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
30 October 2026